Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine®)

Joel Morganroth, Craig Pratt

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

Moricizine was studied in 908 patients with ventricular arrhythmia. Proarrhythmia occurred in 29 (3.2%). When the type of proarrhythmia and the type of ventricular arrhythmia were correlated, no proarrhythmic events occurred in patients with benign ventricular arrhythmia. Three of the 4 deaths due to proarrhythmia occurred in patients with lethal ventricular arrhythmia and 14 of the 15 serious proarrhythmic events occurred in patients with potentially lethal ventricular arrhythmia. The overall proarrhythmia incidence in lethal and potentially lethal ventricular arrhythmias was not different (3.2 vs 3.7%, respectively). Proarrhythmia occurred in patients with more significant structural heart disease or conduction defects at baseline, but was not related to the baseline frequency of ventricular premature complexes. There was no relation between dose of moricizine and incidence of proarrhythmia. All 29 proarrhythmic events occurred within 10 days and 26 of 29 (90%) took place within 7 days of therapy start. Thus, moricizine has a low proarrhythmic potential, especially in patients with lethal ventricular arrhythmias, and may have the best risk/benefit ratio among first-line drugs used in these patients.

Original languageEnglish (US)
Pages (from-to)172-176
Number of pages5
JournalThe American Journal of Cardiology
Volume63
Issue number3
DOIs
StatePublished - Jan 15 1989

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine<sup>®</sup>)'. Together they form a unique fingerprint.

Cite this